Prognostication in cancer of unknown primary (CUP): Development of a prognostic algorithm in 311 cases and review of the literature

Cancer Treatment Reviews

Volumn 39, Issue 7, 2013, Pages 701-708

  Petrakis, Dimitrios ^a   Pentheroudakis, George ^a   Voulgaris, Evangelos ^a   Pavlidis, Nicholas ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Algorithm; Cancer of unknown primary; Prognostic factors; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ALGORITHM; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; HIGH RISK POPULATION; HUMAN; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL TIME;

ALGORITHM; CANCER OF UNKNOWN PRIMARY; PROGNOSTIC FACTORS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; TREATMENT OUTCOME;

EID: 84881551009     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.03.001     Document Type: Review

References (33)

1. Greco F.A., Heinsworth J.D. Cancer of unknown primary site. Cancer Principles and practice of oncology 1997, 2423-2443. J.B. Lippincott Co, Philadelphia. 4th ed. T.V. de Vita, S. Hellman, S.A. Rosenberg (Eds.).
2. Visser O., Coebergh J.W.W., Schouten L.J. Incidence of cancer in the Netherlands 1993 1993, Utrecht, The Netherlands Cancer Registry.
3. Pavlidis N., Briasoulis E., Heinsworth J., Greco F.A. Diagnostic and therapeutic management of cancer of unknown primary. Eur J Cancer 2003, 39:1990-2005.
4. Van Der Wouw A.J., Jansen R.L., Griffoen A.W., Hillen H.F. Clinical and immunoistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res 2004, 24:297-301.
5. Pentheroudakis G., Briasoulis E., Pavlidis N. Cancer of unknown primary site: missing primary or missing biology?. Oncologist 2007, 12(4):418-425.
6. Pavlidis N., Petrakis D., Golfinopoulos V., Pentheroudakis G. Long-term survivors among patients with cancer of unknown primary?. Crit Rev Oncol Hematol 2012, 84(1):85-92.
7. Pavlidis N., Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematolol 2009, 69(3):271-278.
8. Pavlidis N., Pentheroudakis G. Cancer of unknown primary site. Lancet 2012, 379(9824):1428-1435.
9. Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncologica 2007, 46:592-601.
10. Fizasi K., Greco F.A., Pavlidis N., Pentheroudakis G. Cancer of uknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol 2011, 22(Suppl 6):Vi64-Vi68.
11. Alberts A.S., Falkon G., Falkon H.C., Van Der Marve M.P. Treatment and prognosis of metastatic carcinoma of unknown primary: analysis of 100 patients. Med Pediatr Oncol 1989, 17:188-192.
12. Van der Gaast A., Verweij J., Planting A.S., Hop W.C., Stoner G. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 1995, 13(7):1720-1725.
13. Hess K.R., Abbruzzese M.C., Lenzi R., Raber M.N., Abbruzzese J.L. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999, 5(11):3403-3410.
14. Abbruzzese J.L., Abbruzzese M.C., Hess K.R., Raber M.N., Lenzi R., Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994, 12(6):1272-1280.
15. Culine S., Kramar A., Saghatchian M., et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002, 20(24):4679-4683.
16. Culine S. Prognostic factors in unknown primary cancer. Semin Oncol 2009, 36:60-64.
17. Ponce Lorenzo J., Segura Huerta A., Diaz Beverige R., et al. Carcinoma of unknown primary site: development in a single institution of a prognostic model based on a clinical and serum variables. Clin Trans Oncol 2007, 9:452-458.
18. Seve P., Ray-Coquard I., Trillet-Lenoir V., et al. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer 2006, 107:2698-2705.
19. Trivanovic D., Petkovic M., Stimac D. New prognostic index to predict survival in patients with cancer of unknown primary site with unfavourable prognosis. Clin Oncol 2009, 21:43-48.
20. Fernandez-Cotarelo M.J., Guerra-Vales J.M., Colina F., Dela Cruz J. Prognostic factors in cancer of unknown primary site. Tumori 2010, 96:111-116.
21. Kobaira M., Takahashi S., Yamada S., Ueda K., et al. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systemic chemotherapy. Ann Oncol 2010, 21:1163-1167.
22. Pasterz R., Savaraj N., Burgess M. Prognostic factors in metastatic carcinoma of unknown primary. J Clin Oncol 1986, 4(11):1652-1657.
23. Thöm I., Rogers C., Andritzky B., et al. Single center management of 136 patients with cancer of unknown primary site (CUP syndrome) over a period of 10 years. Onkologie 2009, 32:741-746.
24. Piga A., Gesuita R., Catalano V., et al. Identification of clinical prognostic factors in patients with unknown primary tumors treated with a platinum- based combination. Oncology 2005, 69:135-144.
25. Kambhu S.A., Kelsen D.P., Fiore J., et al. Metastatic adenocarcinoma of unknown primary site. Prognostic variables and treatment results. Am J Clin Oncol 1990, 13:55-60.
26. Lu H.J., Chen K.J., Tseng C.H., et al. Evaluation of prognosis for carcinoma of unknown origin in elderly patients. Oncology 2012, 83(1):24-30.
27. Hogan B.A., Thornton F.J., Brannigan M., et al. Hepatic metastases from an unknown primary neoplasm (UPN): survival, prognostic indicators and value of extensive investigations. Clin Radiol 2002, 57:1073-1077.
28. Varadarajan R., Edge S.B., Yu J., et al. Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology 2006, 71:456-459.
29. Millis R.R., Springall R., Lee A.H.S., et al. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br J Cancer 2002, 86:396-401.
30. Van Damme V., Govaerts E., Nackaerts K., Dooms C., Wauters I., Vansteenkiste J. Clinical factors predictive of long-term survival in advanced non-small cell lung cancer. Lung cancer 2013 Jan, 79(1):73-76.
31. Mercadante S., Valle A., Porzio G., Aielli F., Adile C., Casuccio A. Prognostic factors of survival in patients with advanced cancer admitted to home care. J Pain Symptom Manage 2013, 45(1):56-62.
32. Cerny J., Rosmarin A.G. Why does my patient have leukocytosis?. Hematol Oncol Clin North Am 2012, 26(2):303-319.
33. Hainsworth J.D., Rubin M.S., Spigel D.R., Boccia R.V., Raby S., Quinn R., et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the sarah cannon research institute. J Clin Oncol 2013, 31(2):217-223.